Endoscopic Ultrasound-Guided Treatment of Pancreatic Cancer

被引：11

作者：

Cazacu I.M. ^{[1
,2
]}

Singh B.S. ^{[1
]}

Saftoiu A. ^{[2
]}

Bhutani M.S. ^{[1
]}

机构：

[1] Department of Gastroenterology, Hepatology and Nutrition, MD Anderson Cancer Center, The University of Texas, Houston, TX

[2] Research Center of Gastroenterology and Hepatology, University of Medicine and Pharmacy, Craiova

来源：

Current Gastroenterology Reports | 2020年 / 22卷 / 6期

关键词：

Brachytherapy; Endoscopic ultrasound; Fiducial markers; Pancreatic cancer; Radiofrequency ablation;

D O I：

10.1007/s11894-020-00767-1

中图分类号：

学科分类号：

摘要：

Purpose of Review: The aim of this review is to evaluate the emerging role of endoscopic ultrasound (EUS) in the guidance of tumor-targeted therapies for patients with pancreatic cancer (PC). Recent Findings: EUS-guided ablation, brachytherapy, fiducial marker placement, and antitumor agent injection have been described to date. EUS-guided fiducial placement for SBRT in pancreatic cancer has entered the clinical practice and is performed at many centers clinically without a research protocol. EUS-guided brachytherapy and RFA have been shown to be feasible and safe procedures, and potentially offer local disease control. Summary: Other potential techniques of EUS-guided treatment of pancreatic cancer are still considered experimental, with many of them appearing to be safe and reasonably well tolerated. However, their effectiveness and exact role in oncological treatment have yet to be established. Clinical trials with many of the techniques/agents described are underway and multicentric randomized trials with prospective design are eagerly awaited. © 2020, Springer Science+Business Media, LLC, part of Springer Nature.

引用

共 59 条

[1]

Ferlay J., Colombet M., Soerjomataram I., Dyba T., Randi G., Bettio M., Gavin A., Visser O., Bray F., Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018, Eur J Cancer, 103, pp. 356-387, (2018)

[2]

Von Hoff D.D., Et al., Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine, N Engl J Med, 369, 18, pp. 1691-1703, (2013)

[3]

Conroy T., Hammel P., Hebbar M., Ben Abdelghani M., Wei A.C., Raoul J.L., Chone L., Francois E., Artru P., Biagi J.J., Lecomte T., Assenat E., Faroux R., Ychou M., Volet J., Sauvanet A., Breysacher G., di Fiore F., Cripps C., Kavan P., Texereau P., Bouhier-Leporrier K., Khemissa-Akouz F., Legoux J.L., Juzyna B., Gourgou S., O'Callaghan C.J., Jouffroy-Zeller C., Rat P., Malka D., Castan F., Bachet J.B., FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer, N Engl J Med, 379, 25, p

[4]

Surveillance E., And End Results (SEER) Program. Cancer Stat Facts: Pancreatic Cancer., (2018)

[5]

DiMagno E.P., Et al., Ultrasonic endoscope, Lancet, 1, 8169, pp. 629-631, (1980)

[6]

Cazacu I.M., Luzuriaga Chavez A.A., Saftoiu A., Vilmann P., Bhutani M.S., A quarter century of EUS-FNA: progress, milestones, and future directions, Endoscopic Ultrasound, 7, 3, pp. 141-160, (2018)

[7]

Vilmann P., Jacobsen G.K., Henriksen F.W., Hancke S., Endoscopic ultrasonography with guided fine needle aspiration biopsy in pancreatic disease, Gastrointest Endosc, 38, 2, pp. 172-173, (1992)

[8]

Tempero M.A., Et al., Pancreatic adenocarcinoma, version 1.2019, J Natl Compr Cancer Netw, 17, 3, pp. 202-210, (2019)

[9]

Seicean A., Cainap C., Gulei I., Tantau M., Seicean R., Pain palliation by endoscopic ultrasound-guided celiac plexus neurolysis in patients with unresectable pancreatic cancer, J Gastrointestin Liver Dis, 22, 1, pp. 59-64, (2013)

[10]

Doi S., Et al., Endoscopic ultrasound-guided celiac ganglia neurolysis vs. celiac plexus neurolysis: a randomized multicenter trial, Endoscopy, 45, 5, pp. 362-369, (2013)

← 1 2 3 4 5 6 →